A previous analysis from the GO-BEFORE trial of bDMARD-naive patients with RA treated with tumor necrosis factor inhibitor (TNFi) therapy and/or MTX found that MRI synovitis, bone edema, and erosion independently correlated with physical function, pain, and Patient Global Assessment scores [25]. The gene discussed is TNF; the disease is rheumatoid arthritis.